Today: 21 March 2026
Subscribe
Browse Category

NYSE:PFE 14 December 2025 - 21 December 2025

Pfizer Stock (PFE) in Focus: 2026 Guidance, Drug-Price Deal Pressures, and Pipeline Catalysts Investors Are Watching

Pfizer Stock (PFE) in Focus: 2026 Guidance, Drug-Price Deal Pressures, and Pipeline Catalysts Investors Are Watching

Pfizer forecast 2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, both below Wall Street estimates. The company expects a $1.5 billion drop in COVID product sales and another $1.5 billion hit from patent expirations. Pfizer signed a Medicaid pricing deal with the Trump administration, warning of margin compression. Shares closed at $25.25 on Dec. 19.
21 December 2025
··
Pfizer Stock (NYSE: PFE) on Dec. 20, 2025: 2026 Forecast, Dividend Outlook, and the Catalysts Wall Street Is Watching

Pfizer Stock (NYSE: PFE) on Dec. 20, 2025: 2026 Forecast, Dividend Outlook, and the Catalysts Wall Street Is Watching

Pfizer shares traded near $25.19 as of Dec. 20, 2025, following the company’s 2026 guidance projecting $59.5–$62.5 billion in revenue and adjusted EPS of $2.80–$3.00. The stock saw heavy volume after management cited lower COVID sales, patent expiries, and deal dilution as headwinds. U.S. drug-pricing deals and new Medicare pilot programs added pressure.
21 December 2025
····
Pfizer Stock (PFE) News Today: 2026 Guidance, TrumpRx Drug-Pricing Deals, Dividend, and Analyst Forecasts (Dec. 20, 2025)

Pfizer Stock (PFE) News Today: 2026 Guidance, TrumpRx Drug-Pricing Deals, Dividend, and Analyst Forecasts (Dec. 20, 2025)

Pfizer shares closed at $25.19 after a volatile week marked by a sharp selloff following new 2026 guidance. The company forecasted 2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, with COVID-19 product sales expected to drop further. Management signaled no return to revenue growth until 2029, citing patent expirations and pricing pressures.
20 December 2025
···
Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Price Targets, Dividend Outlook and Key Catalysts on Dec. 19, 2025

Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Price Targets, Dividend Outlook and Key Catalysts on Dec. 19, 2025

Pfizer shares closed at $25.37 on Dec. 19, 2025, up 1.3% with volume near 43.5 million. The company forecast 2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, citing lower COVID product sales and patent expirations as key drags. Investors tracked a positive bladder cancer trial and new U.S. drug-pricing rules affecting Pfizer’s portfolio.
19 December 2025
··
Pfizer Stock (PFE) Forecast and News: 2026 Guidance, Drug-Pricing Deals, and Pipeline Catalysts to Watch on Dec. 19, 2025

Pfizer Stock (PFE) Forecast and News: 2026 Guidance, Drug-Pricing Deals, and Pipeline Catalysts to Watch on Dec. 19, 2025

Pfizer shares traded near $25.04 midday Friday after a volatile week, holding steady despite new policy headlines and a guidance reset. The company issued 2026 revenue guidance of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, both below Wall Street estimates. Pfizer also reported positive Phase 3 results for PADCEV + Keytruda in bladder cancer.
19 December 2025
···
Pfizer Stock After Hours Today (Dec. 18, 2025): PFE Holds Near $25 — What to Know Before Friday’s Market Open

Pfizer Stock After Hours Today (Dec. 18, 2025): PFE Holds Near $25 — What to Know Before Friday’s Market Open

Pfizer shares closed Thursday at $25.04 and held near that level in after-hours trading as investors weighed the company’s 2026 outlook and ongoing U.S. drug pricing policy changes. Pfizer forecast 2026 revenue between $59.5 billion and $62.5 billion, and adjusted EPS of $2.80 to $3.00. The company expects COVID-19 product sales to drop to about $5 billion in 2026.
19 December 2025
··
Pfizer Stock (NYSE: PFE) News Today: 2026 Guidance, Analyst Price Targets, Medicare Pricing Pressure, and Pipeline Catalysts (Dec. 18, 2025)

Pfizer Stock (NYSE: PFE) News Today: 2026 Guidance, Analyst Price Targets, Medicare Pricing Pressure, and Pipeline Catalysts (Dec. 18, 2025)

Pfizer shares traded near $25.04 at 18:26 UTC on Dec. 18, steady after a sharp selloff earlier in the week following new 2025 and 2026 guidance. The company now expects 2025 revenue of about $62 billion and 2026 revenue of $59.5–$62.5 billion. Reuters reports highlight policy and pricing pressures, while Pfizer and Astellas announced positive Phase 3 results for PADCEV + Keytruda in bladder cancer.
18 December 2025
Pfizer Stock (PFE) on Dec. 18, 2025: Latest News, 2026 Forecast, Analyst Price Targets, Dividend, and Key Catalysts

Pfizer Stock (PFE) on Dec. 18, 2025: Latest News, 2026 Forecast, Analyst Price Targets, Dividend, and Key Catalysts

Pfizer shares traded at $25.04 on Dec. 18, 2025, down 1.8% after management issued cautious 2026 guidance with revenue forecast at $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00. The company cited lower COVID product sales and patent expirations as major headwinds. Pfizer stock has dropped over 50% since early 2023. Investors remain focused on its dividend yield and oncology developments.
18 December 2025
··
Pfizer Stock (PFE) After Hours Today (Dec. 17, 2025): What to Know Before the Market Opens Thursday

Pfizer Stock (PFE) After Hours Today (Dec. 17, 2025): What to Know Before the Market Opens Thursday

Pfizer shares closed down 1.9% at $25.04 Wednesday, hitting session lows despite positive Phase 3 results for PADCEV plus KEYTRUDA in bladder cancer. The stock edged up to $25.07 after hours. Investors weighed new 2026 guidance projecting $59.5–$62.5 billion in revenue and a $1.5 billion decline in COVID-19 product sales. Broader U.S. market weakness also pressured the stock.
18 December 2025
··
Pfizer Stock (PFE) Today: 2026 Guidance Triggers Fresh Scrutiny—News, Forecasts, Analyst Targets and Dividend Outlook (Dec. 17, 2025)

Pfizer Stock (PFE) Today: 2026 Guidance Triggers Fresh Scrutiny—News, Forecasts, Analyst Targets and Dividend Outlook (Dec. 17, 2025)

Pfizer shares traded near $25.50 Wednesday after the company issued 2026 revenue guidance of $59.5–$62.5 billion and forecast adjusted EPS of $2.80–$3.00, below Wall Street expectations. The company also cut its 2025 revenue outlook to about $62 billion. Shares fell about 5% after the update. Pfizer cited lower COVID product sales and ongoing patent losses as key headwinds.
17 December 2025
···
Pfizer Stock (PFE) Slips After 2026 Outlook: Guidance, Analyst Forecasts, Dividend Update, and Key Catalysts to Watch on Dec. 17, 2025

Pfizer Stock (PFE) Slips After 2026 Outlook: Guidance, Analyst Forecasts, Dividend Update, and Key Catalysts to Watch on Dec. 17, 2025

Pfizer shares fell 3.4% to $25.53 Wednesday after the company cut its 2025 revenue forecast to about $62 billion and issued 2026 guidance below analyst expectations. Pfizer now projects 2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00. COVID-19 product sales are expected to drop to $5 billion in 2026. No share repurchases are planned for 2025 or 2026.
17 December 2025
···
Pfizer Stock (NYSE: PFE) News Today: 2026 Guidance, Earnings Forecasts, Analyst Price Targets and Key Catalysts

Pfizer Stock (NYSE: PFE) News Today: 2026 Guidance, Earnings Forecasts, Analyst Price Targets and Key Catalysts

Pfizer shares fell 3.4% to $25.53 late Dec. 16 after the company issued 2026 guidance projecting flat-to-declining revenue and adjusted EPS of $2.80–$3.00. The outlook cited lower COVID product sales and a $1.5 billion hit from patent expirations. Pfizer expects no share buybacks through 2026. Wall Street noted the EPS target is slightly below consensus.
17 December 2025
····
Pfizer Stock After Hours Today (Dec. 16, 2025): PFE Drops on 2026 Outlook—What to Know Before the Market Opens Dec. 17

Pfizer Stock After Hours Today (Dec. 16, 2025): PFE Drops on 2026 Outlook—What to Know Before the Market Opens Dec. 17

Pfizer shares fell 3.41% to $25.53 Tuesday after the company issued 2026 guidance below Wall Street expectations, then slipped further after hours. Pfizer forecast 2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, both trailing analyst estimates. The company cited lower COVID product sales and loss of exclusivity as key headwinds. Pfizer does not expect revenue growth to return until 2029, according to Reuters.
16 December 2025
·
Pfizer Stock (PFE) Slides After 2026 Guidance: COVID Sales Drop, Patent Cliff and Analyst Forecasts in Focus

Pfizer Stock (PFE) Slides After 2026 Guidance: COVID Sales Drop, Patent Cliff and Analyst Forecasts in Focus

Pfizer shares fell nearly 5% to about $25 in U.S. trading Tuesday after the company issued 2026 guidance with adjusted EPS of $2.80–$3.00, below Wall Street estimates. The stock reversed early gains as investors reacted to lower COVID-19 sales and patent expirations expected to pressure results next year. Trading volume topped 55 million shares by late morning.
16 December 2025
····
Pfizer Forecasts Flat 2026 Sales and Lower Profit as COVID Demand Falls; PFE Dividend Remains $0.43

Pfizer Forecasts Flat 2026 Sales and Lower Profit as COVID Demand Falls; PFE Dividend Remains $0.43

Pfizer projected 2026 revenue of $59.5 billion to $62.5 billion and adjusted EPS of $2.80 to $3.00, both below Wall Street estimates. The company cited falling COVID-19 product sales and loss of exclusivity for key drugs as main drags. Shares were little changed Tuesday after the update. Pfizer expects about $5 billion in COVID product revenue for 2026, down from $6.5 billion in 2025.
16 December 2025
···
Pfizer Stock After Hours (PFE) on Dec. 15, 2025: What Moved Shares Today—and What to Watch Before Tuesday’s Open

Pfizer Stock After Hours (PFE) on Dec. 15, 2025: What Moved Shares Today—and What to Watch Before Tuesday’s Open

Pfizer shares closed Monday at $26.43, up 2.24%, then slipped to $26.34 after hours. Investors are awaiting Tuesday’s analyst call, where management is set to outline 2026 guidance. The company announced a new autoimmune research deal with Adaptive Biotechnologies, worth up to $890 million in milestones. Trading volume was about 60 million shares, below average.
16 December 2025
···
Pfizer Stock (PFE) News, Forecasts, and Analyst Outlook: What’s Driving Shares on December 15, 2025

Pfizer Stock (PFE) News, Forecasts, and Analyst Outlook: What’s Driving Shares on December 15, 2025

Pfizer shares traded near $26.36 on December 15, 2025, close to their 52-week high, with a market cap around $150 billion. The company announced new immunology research agreements with Adaptive Biotechnologies worth up to $890 million. Investors are awaiting Pfizer’s full-year 2026 guidance call scheduled for December 16. Dividend yield stands at about 6.5%, with analyst consensus broadly Hold.
15 December 2025
··
Pfizer Stock (PFE) News Today: Dividend, 2026 Guidance Call, Obesity Deals, and Analyst Forecasts (Dec. 15, 2025)

Pfizer Stock (PFE) News Today: Dividend, 2026 Guidance Call, Obesity Deals, and Analyst Forecasts (Dec. 15, 2025)

Pfizer shares traded at $25.85 as of 12:08 UTC Monday, unchanged from Friday’s close. The company will hold a conference call Tuesday morning to provide full-year 2026 financial guidance. Pfizer’s board declared a $0.43 first-quarter 2026 dividend, marking its 349th consecutive quarterly payout. Market cap stands near $147 billion.
15 December 2025
····
Pfizer Stock (PFE) Before Market Open Dec. 15, 2025: Key News, 2026 Guidance Call, Analyst Targets, Dividend, and Risks

Pfizer Stock (PFE) Before Market Open Dec. 15, 2025: Key News, 2026 Guidance Call, Analyst Targets, Dividend, and Risks

Pfizer closed Friday at $25.85, near the upper end of its 52-week range. Investors are focused on the company’s analyst call Tuesday, where management will issue 2026 financial guidance. Pfizer’s dividend yield remains in the mid-6% range, while short interest stands at about 2.45% of float. Policy uncertainty for COVID vaccines and efforts to grow oncology and cardiometabolic revenue remain in focus.
14 December 2025
··
1 … 3 4 5 6 7 … 10

Stock Market Today

  • Freeport McMoRan (FCX) Undervalued Despite Recent Price Drop, Analysis Shows
    March 21, 2026, 12:53 PM EDT. Freeport-McMoRan's share price dropped 7.6% last week and 16.7% in the past month, trading at $52.09, yet remains up 31.2% over the past year. The company shows a strong long-term return of 69.3% over five years. A Discounted Cash Flow (DCF) model estimates its intrinsic value at $84.26 per share, suggesting the stock is undervalued by 38.2%. Despite a high price-to-earnings (P/E) ratio of 34.1x compared to industry averages, the DCF implies potential upside. Investors are weighing recent commodity market dynamics and metals sector shifts, making FCX a key focus for valuation analysis.
Go toTop